Current status of syphilis vaccine development: Need, challenges, prospects
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Syphilis is a multistage disease caused by the invasive spirochete Treponema pallidum subsp. pallidum. Despite inexpensive and effective antibiotic therapy, syphilis remains a prevalent disease in developing countries and has re-emerged as a public health threat in developed nations. In addition to the medical burden imparted by infectious syphilis, congenital syphilis is considered the most significant infectious disease affecting fetuses and newborns worldwide, and individuals afflicted with syphilis have an enhanced risk for HIV transmission and acquisition. The global disease burden of syphilis and failure of decades of public health efforts to stem the incidence of disease highlight the need for an effective syphilis vaccine. Although challenges associated with T. pallidum research have impeded understanding of this pathogen, the existence of a relevant animal model has enabled insight into the correlates of disease protection. Complete protection against infection has been achieved in the animal model using an extended immunization regimen of γ-irradiated T. pallidum, demonstrating the importance of treponemal surface components in generation of protective immunity and the feasibility of syphilis vaccine development. Syphilis is a prime candidate for development of a successful vaccine due to the (1) research community’s accumulated knowledge of immune correlates of protection; (2) existence of a relevant animal model that enables effective pre-clinical analyses; (3) universal penicillin susceptibility of T. pallidum which enhances the attractiveness of clinical vaccine trials; and (4) significant public health benefit a vaccine would have on reduction of infectious/congenital syphilis and HIV rates. Critical personnel, research and market gaps need to be addressed before the goal of a syphilis vaccine can be realized, including recruitment of additional researchers to the T. pallidum research field with a proportional increase in research funding, attainment of a definitive understanding of correlates of protection in humans, and engagement of industry/funding partnerships for syphilis vaccine production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Lukehart, S. A., Hook, E. W., Baker-Zander, S. A., Collier, A. C., Critchlow, C. W., & Handsfield, H. H. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-11-855 · Cited by 603 · cited 1×
“pallidum is most dramatically illustrated by the ability of the pathogen to cross the placental barrier to cause CS and by the fact that at least 40% of patients with early syphilis have CNS invasion [37].”
BackgroundSelf-citationNewman, L., Kamb, M., Hawkes, S., Gomez, G., Say, L., Seuc, A., & Broutet, N. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001396 · Cited by 448 · cited 1×
“36 million pregnant women presenting with syphilis, 20% had not attended ANC and 66% of infected women who did attend ANC still had adverse outcomes due to lack of either syphilis testing or treatment [30].”
BackgroundINOCULATION SYPHILIS IN HUMAN VOLUNTEERS
MAGNUSON, H. J., THOMAS, E. W., OLANSKY, S., KAPLAN, B. I., MELLO, L. D., & CUTLER, J. C. (1956) · Medicine · doi:10.1097/00005792-195602000-00002 · Cited by 273 · cited 1×
“pallidum, but that those with earlier stages show evidence of infection following challenge [95].”
BackgroundSyphilis in Pregnancy in Tanzania. I. Impact of Maternal Syphilis on Outcome of Pregnancy
Watson‐Jones, D., Changalucha, J., Gumodoka, B., Weiss, H., Rusizoka, M., Ndeki, L., Whitehouse, A., Balira, R., Todd, J., Ngeleja, D., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/342952 · Cited by 261 · cited 1×
“Congenital syphilis (CS) remains a significant global public health concern and is considered the most common infection associated with fetal loss or stillbirth in low income settings [15;16].”
Background
Cited by
Peeling, R. W., Mabey, D., Kamb, M. L., Chen, X.-S., Radolf, J. D., & Benzaken, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.73 · Cited by 664
An Update on the Global Epidemiology of Syphilis
Kojima, N., & Klausner, J. D. (2018) · Current Epidemiology Reports · doi:10.1007/s40471-018-0138-z · Cited by 379
Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen
Radolf, J. D., Deka, R. K., Anand, A., Šmajs, D., Norgard, M. V., & Yang, X. F. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.141 · Cited by 320
Resurgence of congenital syphilis: new strategies against an old foe
Moseley, P., Bamford, A., Eisen, S., Lyall, H., Kingston, M., Thorne, C., Piñera, C., Rabie, H., Prendergast, A. J., & Kadambari, S. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00314-6 · Cited by 84
Hussen, S., & Tadesse, B. T. (2019) · BioMed Research International · doi:10.1155/2019/4562385 · Cited by 63
Metadata
- Authors
- Cameron, C. E., & Lukehart, S. A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 32
- Issue
- 14
- Pages
- 1602-1609
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2029913194
- Cited by
- 87
- References
- 5
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current status of syphilis vaccine development: Need, challenges, prospects. https://app.cochat.ai/papers/10.1016/j.vaccine.2013.09.053
- The paper
- Cameron, C. E., & Lukehart, S. A. (2014). Current status of syphilis vaccine development: Need, challenges, prospects. Vaccine. https://doi.org/10.1016/j.vaccine.2013.09.053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.